PSMA

Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA). This compound is utilized in SPECT/CT imaging, providing valuable insights into the cellular profiles of triple-negative breast cancer and prostate cancer. Its application in radionuclide studies underscores its significance in cancer research and therapeutic development.

Tert-Butyl-DCL is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA), a crucial target in prostate cancer research. Its inhibition of PSMA activity makes Tert-Butyl-DCL a valuable tool for studying the molecular mechanisms of prostate cancer progression and therapeutic interventions. This compound is ideal for applications in cancer biology and the development of PSMA-targeted therapies.

GCPII-IN-1 is a potent inhibitor of the gene carboxypeptidase II (GCPII), also recognized as prostate-specific membrane antigen (PSMA), with a Ki value of 44.3 nM. This compound is primarily utilized in the research of prostate cancer, facilitating studies aimed at understanding tumor biology and developing potential therapeutic strategies. Its mechanism of action makes it a valuable tool for elucidating the role of GCPII in cancer progression.

GCPII-IN-1 TFA is a selective inhibitor of GCPII (glutamate carboxypeptidase II), also known as prostate-specific membrane antigen (PSMA), exhibiting a Ki value of 44.3 nM. This compound is instrumental in the investigation of prostate cancer, facilitating studies on the modulation of GCPII activity and its potential therapeutic applications in oncology. Researchers can utilize GCPII-IN-1 TFA to explore mechanisms of tumor growth and treatment resistance in prostate cancer models.

PSMA–DA1 is a radioactive inhibitor targeting Prostate-Specific Membrane Antigen (PSMA). It serves as a promising radiotheranostic agent for imaging and treating PSMA-expressing tumors. Its specificity for PSMA makes it a valuable tool in the research of prostate cancer diagnosis and therapy, enabling the development of effective targeted treatment strategies.

MIP-1072 is a selective inhibitor of prostate-specific membrane antigen (PSMA) that targets the enzyme's glutamate carboxypeptidase activity. With a Ki value of 4.6 nM, MIP-1072 demonstrates significant potency in inhibiting PSMA, making it a valuable tool in prostate cancer research. Its application is particularly relevant for studies focused on the role of PSMA in tumor progression and targeted therapies.

MIP-1095 is a potent inhibitor of prostate-specific membrane antigen (PSMA), specifically targeting its glutamate carboxypeptidase activity with a Ki of 0.24 nM. This compound is valuable in research applications focused on prostate cancer, facilitating studies on PSMA's role in tumor progression and its potential as a therapeutic target. MIP-1095 is essential for the development of PSMA-targeted diagnostics and therapeutics.

PSMA-IN-4 is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting an IC50 value of 1.2 μM. This compound effectively interferes with PSMA activity, making it a valuable tool in research focused on prostate cancer diagnostics and therapeutics. Its specificity and potency support investigations into PSMA's role in tumor biology and its potential as a therapeutic target.

PSMA-IN-2 is a potent inhibitor of Prostate-Specific Membrane Antigen (PSMA) with a Ki value of 1.07 nM. This compound exhibits promising in vivo near-infrared (NIR) imaging properties at an emission wavelength of 1088 nm and an excitation wavelength of 808 nm. PSMA-IN-2 is particularly applicable in NIRII image-guided tumor resection surgeries in models of PSMA-positive tumors, making it a valuable tool for cancer research and therapeutic interventions.

PSMA-IN-3 is a high-affinity inhibitor of Prostate-Specific Membrane Antigen (PSMA), demonstrating an IC50 value of 13 nM. This compound is particularly relevant for the development of 18F-labeled radioligands for positron emission tomography (PET) imaging to detect PSMA expression in prostate cancer. Researchers can utilize PSMA-IN-3 for studies aimed at advancing diagnostic imaging and therapeutic strategies in oncology.

DCFBC is a potent prostate-specific membrane antigen (PSMA) inhibitor, primarily utilized for small animal positron emission tomography (PET) imaging applications. Labeled with fluorine-18, [18F]DCFBC demonstrates preferential uptake in PSMA-expressing tumors, particularly in PIP tumors, while showing minimal uptake in FLU tumors. Additionally, while high accumulation in the kidneys and bladder is observed, the washout of radioactivity is faster compared to PIP tumors. This specificity positions [18F]DCFBC as a valuable tool for studying prostate cancer and assessing PSMA-targeted therapies.

(R)-Zadavotide guraxetan is a potent inhibitor of prostate-specific membrane antigen (PSMA), exhibiting significant antitumor activity. It is primarily utilized in research focused on prostate cancer, contributing to the understanding of targeted therapeutic approaches. This compound serves as a valuable tool for investigating the role of PSMA in cancer biology and evaluating efficacy in preclinical studies.